Summer Intern - Sales Training & Operations

Karyopharm Therapeutics Inc.

Jan 23

Applications are closed

Internship
Full-time
Starts on May 26
Summer Internship
Sales & Business Development
Healthcare

Requirements

Area of study should be in a business, marketing or healthcare related focus with an interest in a career in the medical or biotech field.
A solid foundation of general experience with both PowerPoint and Excel is required and examples of this in the interview process would be beneficial.
Ability to support all time zones in which are field teams reside (U.S. Only)
Virtually meeting skill sets and the ability to complete projects with minimal supervision.
You have a strong interest in life sciences and are passionate about giving patients with cancer a chance to enjoy more of life’s precious moments.
You feel a strong connection with our ICARE values (Innovation, Courage, Alignment & Accountability, Resilience, and Energy)
You demonstrate enthusiasm for learning and a commitment to career development

Responsibilities

Train on disease states related to current FDA approved indications in two hematologic malignancies.
With direction from management, maintain platforms and dashboards with up to date content.
Create PowerPoint decks and Excel spreadsheets for team presentations and projects as needed.
Engage in projects yet to be determined with members from field team.

Karyopharm Therapeutics Inc.

Targeting Disease at the Nuclear Pore

Manufacturing & Electronics

Industry

201-500

Employees

2008

Founded Year

Mission & Purpose

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.